Annovis Bio, Inc. (ANVS)

NYSE: ANVS · IEX Real-Time Price · USD
11.57
-0.28 (-2.36%)
At close: Dec 9, 2022 4:00 PM
11.71
+0.14 (1.21%)
After-hours: Dec 9, 2022 4:11 PM EST
-2.36%
Market Cap 96.74M
Revenue (ttm) n/a
Net Income (ttm) -28.15M
Shares Out 8.16M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,140
Open 11.69
Previous Close 11.85
Day's Range 11.4 - 12.09
52-Week Range 8.39 - 23.91
Beta 1.22
Analysts Buy
Price Target 46.92 (+305.5%)
Earnings Date Nov 9, 2022

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. T... [Read more]

Industry Biotechnology
IPO Date Jan 29, 2020
CEO Maria Maccecchini
Employees 3
Stock Exchange NYSE
Ticker Symbol ANVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ANVS stock is "Buy." The 12-month stock price forecast is 46.92, which is an increase of 305.53% from the latest price.

Price Target
$46.92
(305.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 251.4% in Annovis Bio, Inc. (ANVS). While the effectiveness of this highly sought-after metric is questionable, t...

1 week ago - Zacks Investment Research

Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade

The mean of analysts' price targets for Annovis Bio, Inc. (ANVS) points to a 239.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among...

3 weeks ago - Zacks Investment Research

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update

BERWYN, Penn. , Nov. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced t...

1 month ago - PRNewsWire

Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

BERWYN, Pa. , Oct. 20, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it w...

1 month ago - PRNewsWire

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

BERWYN, Pa. , Oct. 11, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today announce...

1 month ago - PRNewsWire

Annovis (ANVS) Gains on FDA Authorization for AD Study

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

2 months ago - Zacks Investment Research

Why Is Annovis Bio (ANVS) Stock Up 12% Today?

Source: pathdoc / Shutterstock.com Annovis Bio (NYSE: ANVS ) stock is getting a boost on Thursday following news that the company will proceed with its Alzheimer's Disease clinical trial. FDA has signed...

2 months ago - InvestorPlace

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease

BERWYN, Pa. , Oct. 6, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today...

2 months ago - PRNewsWire

Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference

BERWYN, Pa. , Sept. 29, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that it ...

2 months ago - PRNewsWire

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Diseas...

BERWYN, Pa. , Sept. 13, 2022 /PRNewswire/ -- (NYSE: ANVS) Annovis Bio ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today the publ...

2 months ago - PRNewsWire

Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

BERWYN, Pa. , Sept. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, today released...

3 months ago - PRNewsWire

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

BERWYN, Pa. , Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appoi...

3 months ago - PRNewsWire

Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

3 months ago - Zacks Investment Research

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

BERWYN, Pa. , Aug. 24, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced toda...

3 months ago - PRNewsWire

Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update

BERWYN, Pa. , Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced sec...

4 months ago - PRNewsWire

Annovis Bio to Participate on Alzheimer's Association International Conference Panel

The Panel will be Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D. BERWYN, Pa.

4 months ago - PRNewsWire

Annovis Bio to Present at the Alzheimer's Association International Conference

Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, ...

4 months ago - PRNewsWire

Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update

Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial. The post Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update appea...

5 months ago - InvestorPlace

FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap

Annovis Bio Inc (NYSE: ANVS) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.  The FDA accepted the final protocol and the clinical...

5 months ago - Benzinga

Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease BERWYN, Pa. , July 7, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("A...

5 months ago - PRNewsWire

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Inf...

Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection...

6 months ago - PRNewsWire

Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today an...

7 months ago - Newsfile Corp

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

Collaboration to Develop Pharmacodynamic Biomarkers for BuntanetapBerwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage ...

7 months ago - Newsfile Corp

Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pl...

7 months ago - Newsfile Corp

Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...

8 months ago - Newsfile Corp